login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SPRUCE BIOSCIENCES INC (SPRB) Stock News
USA
- NASDAQ:SPRB -
US85209E2081
-
Common Stock
112.66
USD
-2.95 (-2.55%)
Last: 11/11/2025, 5:25:36 PM
115.5
USD
+2.84 (+2.52%)
After Hours:
11/11/2025, 5:25:36 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SPRB Latest News, Press Relases and Analysis
All
Press Releases
a day ago - By: Chartmill
Spruce Biosciences Inc (NASDAQ:SPRB) Reports Q3 2025 Results, Secures $50M Financing and Breakthrough Therapy Designation
a day ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
a month ago - By: Benzinga
- Mentions:
XTLB
ESPR
KPTI
XBIO
...
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
a month ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Announces $50.0 Million Private Placement Financing
a month ago - By: Benzinga
- Mentions:
SNWV
CLRB
APVO
GLTO
...
12 Health Care Stocks Moving In Tuesday's Intraday Session
a month ago - By: Stocktwits
SPRB Stock Hits 19-Month High Amid Trading Halts
a month ago - By: Stocktwits
Spruce Biosciences Stock Nearly Doubles Premarket: 'Pharma Bro' Martin Shkreli Sees 280% Upside
a month ago - By: Investor's Business Daily
Why Spruce Biosciences Just Skyrocketed More Than 1,600%
a month ago - By: Stocktwits
Spruce Biosciences Stock More Than Quadruples After Breakthrough Therapy Designation To Therapy For Rare And Fatal Genetic Disease
a month ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
2 months ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
3 months ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
3 months ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
3 months ago - By: Zacks Investment Research
- Mentions:
PBYI
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
CRIS
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
ILMN
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
4 months ago - By: Spruce Biosciences, Inc.
Spruce Biosciences Announces Reverse Stock Split
4 months ago - By: HMNC Holding GmbH
HMNC Brain Health and Spruce Biosciences Announce First Patient Dosed in Phase 2 TAMARIND Trial For Major Depressive Disorder
5 months ago - By: Spruce Biosciences, Inc.
- Mentions:
OTC
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
6 months ago - By: Spruce Biosciences, Inc.
- Mentions:
OTC
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Please enable JavaScript to continue using this application.